ASX Announcements
This Month
Why Rio Tinto is worth more than its $130 price tag
Maple-Brown Abbott’s Emma Pringle is betting the iron ore giant’s share price has more room to run. She’s also bullish on Healius despite a shaky 12 months.
- Joanne Tran
March
Healius in management shake-up after CEO exit
Australia’s No.2 pathology group is cutting costs in a restructure to try to turn around a profit slump, as UBS pushes on with a strategic review.
- Simon Evans
Making excuses for weak margins has ended: Healius CEO
In a closed-door staff briefing, the new boss of the struggling pathology group said the company had not “done a good enough job” of setting up “for success”.
- Simon Evans
Dimon on recession, bubbles and Trump | Dutton backs four-year terms | Lowe’s new gig
Read everything that’s happened in the news so far today.
Healius brings in UBS as it reviews strategy, considers asset sales
The company replaced its chief executive, Maxine Jacquet, earlier this month after just 12 months. It runs some 2000 pathology centres and 100 laboratories.
- Simon Evans
- Opinion
- Chanticleer
How a little acquisition exposed Healius’ core and has heads rolling
Inbuilt system growth covered the cracks for years. Now there is nowhere to hide and its two-pronged pathology/radiology strategy will be consigned to history.
- Anthony Macdonald
Healius CEO exits as strategic review speeds up
Maxine Jaquet is leaving Australia’s second-largest pathology company, with private equity players likely circling in what may end in a break-up of the company.
- Simon Evans
February
Healius flags asset sales and plans to shut some operations
But the country’s second-largest pathology group cannot say what assets are being considered for sale after it recorded a collapse in margins since June 30.
- Simon Evans
December 2023
ACL pulls Healius bid as ACCC blocks pathology shake-up
Australian Clinical Labs, the No.3 player in the pathology market, has not given up in its chase for ailing No.2 player Healius.
- Simon Evans
- Opinion
- Retail
Health, the new frontier for Wesfarmers, Woolworths
Wesfarmers and Woolworths are uniquely positioned to disrupt the health sector by building ecosystems in partnership with insurers and care providers, says Jarden.
- Sue Mitchell
Why it’s so hard to make money from blood tests
There’s restructuring ahead at the No. 2 pathology provider Healius, which despite its activist ructions, has yielded a 30 per cent return since its 2023 low.
- Simon Evans
November 2023
Healius chairwoman exits without apology for $2b wipeout
Departing Healius chairwoman Jenny Macdonald understands shareholder “frustration” but would not apologise for $2b of value destruction.
- Simon Evans
Healius slammed over withheld patient data
Health Minister Mark Butler says test results have been withheld from the My Health Record digital platform since mid-September.
- Tom McIlroy
- Opinion
- Chanticleer
Healius chair’s head on a stick shows investors out of patience
If the healthcare company can’t pull up its socks in the medium term, expect investors to push the board to think about other ways to realise value.
- Anthony Macdonald
- Opinion
- Investing
Healius equity issue highlights need for long-term domestic debt
Most companies have to rely on either low-cost but short-tenor debt, or expensive equity. There need to be other flavours of capital available.
- John Wylie
BGH Capital ready to bare its fangs at Healius over 2020 deal
Melbourne private equity firm BGH Capital has tossed another item on ASX-listed Healius’s growing pile of worries.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Healius chairwoman exits as ‘no’ vote looms
Proxy votes show Jenny Macdonald would have failed in her re-election campaign for the Healius board, which is being targeted by Tanarra Capital.
- Simon Evans
ACL accuses Wylie of hiding links to independent Healius director
But the Tanarra Capital founder, the pathology group’s second-largest investor, says ACL is a “frustrated unsuccessful bidder”.
- Simon Evans
Healius boss says company’s economics have been upended as wages rise
Maxine Jaquet also cited record rents as she defended the company’s performance against criticism from major investor Tanarra Capital.
- Simon Evans
Wylie’s Tanarra circulates Healius attack letter as shares slide
The valuation of the pathology group crashed following a rights issue at a hefty discount to reduce debt levels and relieve pressure from lenders.
- Simon Evans
